143.97 USD
-3.02 (-2.05%)
143.97 USD
0 (0%)
Overall ILMN gets a fundamental rating of 5 out of 10. We evaluated ILMN against 57 industry peers in the Life Sciences Tools & Services industry. While ILMN has a great profitability rating, there are some minor concerns on its financial health. ILMN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- ILMN had positive earnings in the past year.
- ILMN had a positive operating cash flow in the past year.
- In multiple years ILMN reported negative net income over the last 5 years.
- Each year in the past 5 years ILMN had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 11.38%, ILMN belongs to the top of the industry, outperforming 91.23% of the companies in the same industry.
- ILMN has a Return On Equity of 29.53%. This is amongst the best in the industry. ILMN outperforms 96.49% of its industry peers.
- ILMN's Return On Invested Capital of 16.40% is amongst the best of the industry. ILMN outperforms 91.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROIC | 16.4% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ILMN's Profit Margin of 16.39% is amongst the best of the industry. ILMN outperforms 89.47% of its industry peers.
- Looking at the Operating Margin, with a value of 20.41%, ILMN belongs to the top of the industry, outperforming 85.96% of the companies in the same industry.
- In the last couple of years the Operating Margin of ILMN has declined.
- ILMN's Gross Margin of 66.74% is amongst the best of the industry. ILMN outperforms 87.72% of its industry peers.
- ILMN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% |
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
2. Health
2.1 Basic Checks
- ILMN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- ILMN has about the same amout of shares outstanding than it did 1 year ago.
- ILMN has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for ILMN is higher compared to a year ago.
2.2 Solvency
- An Altman-Z score of 4.71 indicates that ILMN is not in any danger for bankruptcy at the moment.
- ILMN's Altman-Z score of 4.71 is fine compared to the rest of the industry. ILMN outperforms 77.19% of its industry peers.
- The Debt to FCF ratio of ILMN is 1.99, which is an excellent value as it means it would take ILMN, only 1.99 years of fcf income to pay off all of its debts.
- With an excellent Debt to FCF ratio value of 1.99, ILMN belongs to the best of the industry, outperforming 87.72% of the companies in the same industry.
- A Debt/Equity ratio of 0.42 indicates that ILMN is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.42, ILMN is in line with its industry, outperforming 40.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Altman-Z | 4.71 |
ROIC/WACC1.52
WACC10.82%
2.3 Liquidity
- A Current Ratio of 1.43 indicates that ILMN should not have too much problems paying its short term obligations.
- ILMN has a Current ratio of 1.43. This is in the lower half of the industry: ILMN underperforms 77.19% of its industry peers.
- ILMN has a Quick Ratio of 1.12. This is a normal value and indicates that ILMN is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of ILMN (1.12) is worse than 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 152.02% over the past year.
- The earnings per share for ILMN have been decreasing by -17.93% on average. This is quite bad
- ILMN shows a decrease in Revenue. In the last year, the revenue decreased by -2.32%.
- ILMN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.29% yearly.
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
3.2 Future
- ILMN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 24.95% yearly.
- The Revenue is expected to grow by 3.99% on average over the next years.
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.95%
Revenue Next Year-0.86%
Revenue Next 2Y0.68%
Revenue Next 3Y2.56%
Revenue Next 5Y3.99%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 33.02, which means the current valuation is very expensive for ILMN.
- Compared to the rest of the industry, the Price/Earnings ratio of ILMN indicates a somewhat cheap valuation: ILMN is cheaper than 68.42% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.33, ILMN is valued a bit more expensive.
- With a Price/Forward Earnings ratio of 28.09, ILMN can be considered very expensive at the moment.
- ILMN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ILMN is cheaper than 71.93% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of ILMN to the average of the S&P500 Index (24.12), we can say ILMN is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.02 | ||
| Fwd PE | 28.09 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, ILMN is valued a bit cheaper than 78.95% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, ILMN is valued cheaply inside the industry as 85.96% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22 | ||
| EV/EBITDA | 19.95 |
4.3 Compensation for Growth
- ILMN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- ILMN has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as ILMN's earnings are expected to grow with 34.05% in the coming years.
PEG (NY)0.34
PEG (5Y)N/A
EPS Next 2Y44.64%
EPS Next 3Y34.05%
5. Dividend
5.1 Amount
- No dividends for ILMN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
143.97
-3.02 (-2.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-30 2025-10-30/amc
Earnings (Next)02-05 2026-02-05/amc
Inst Owners104.7%
Inst Owner Change0.59%
Ins Owners0.17%
Ins Owner Change-0.21%
Market Cap22.00B
Revenue(TTM)4.29B
Net Income(TTM)703.00M
Analysts73.33
Price Target126.28 (-12.29%)
Short Float %4.86%
Short Ratio4.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.9%
Min EPS beat(2)12.52%
Max EPS beat(2)15.27%
EPS beat(4)3
Avg EPS beat(4)5.34%
Min EPS beat(4)-7.76%
Max EPS beat(4)15.27%
EPS beat(8)6
Avg EPS beat(8)97.15%
EPS beat(12)10
Avg EPS beat(12)231.96%
EPS beat(16)13
Avg EPS beat(16)178.01%
Revenue beat(2)0
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)-0.28%
Revenue beat(4)0
Avg Revenue beat(4)-0.66%
Min Revenue beat(4)-1.21%
Max Revenue beat(4)-0.18%
Revenue beat(8)3
Avg Revenue beat(8)-0.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.57%
Revenue beat(16)5
Avg Revenue beat(16)-0.78%
PT rev (1m)2.26%
PT rev (3m)10.92%
EPS NQ rev (1m)-0.06%
EPS NQ rev (3m)3.08%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)4.26%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.02 | ||
| Fwd PE | 28.09 | ||
| P/S | 5.13 | ||
| P/FCF | 22 | ||
| P/OCF | 19.61 | ||
| P/B | 9.24 | ||
| P/tB | 21.09 | ||
| EV/EBITDA | 19.95 |
EPS(TTM)4.36
EY3.03%
EPS(NY)5.13
Fwd EY3.56%
FCF(TTM)6.54
FCFY4.55%
OCF(TTM)7.34
OCFY5.1%
SpS28.06
BVpS15.58
TBVpS6.83
PEG (NY)0.34
PEG (5Y)N/A
Graham Number39.1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.38% | ||
| ROE | 29.53% | ||
| ROCE | 20.76% | ||
| ROIC | 16.4% | ||
| ROICexc | 23.54% | ||
| ROICexgc | 43.23% | ||
| OM | 20.41% | ||
| PM (TTM) | 16.39% | ||
| GM | 66.74% | ||
| FCFM | 23.32% |
ROA(3y)-22.28%
ROA(5y)-10.63%
ROE(3y)-46.16%
ROE(5y)-23.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-6.48%
ROICexc growth 3YN/A
ROICexc growth 5Y-9.28%
OM growth 3YN/A
OM growth 5Y-11.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.07%
GM growth 5Y-1.23%
F-Score7
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.42 | ||
| Debt/FCF | 1.99 | ||
| Debt/EBITDA | 0.86 | ||
| Cap/Depr | 44.36% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.57% | ||
| Profit Quality | 142.25% | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.12 | ||
| Altman-Z | 4.71 |
F-Score7
WACC10.82%
ROIC/WACC1.52
Cap/Depr(3y)66.6%
Cap/Depr(5y)76.75%
Cap/Sales(3y)5.82%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)152.02%
EPS 3Y-25.65%
EPS 5Y-17.93%
EPS Q2Q%17.54%
EPS Next Y96.03%
EPS Next 2Y44.64%
EPS Next 3Y34.05%
EPS Next 5Y24.95%
Revenue 1Y (TTM)-2.32%
Revenue growth 3Y-1.15%
Revenue growth 5Y4.29%
Sales Q2Q%0.37%
Revenue Next Year-0.86%
Revenue Next 2Y0.68%
Revenue Next 3Y2.56%
Revenue Next 5Y3.99%
EBIT growth 1Y154.36%
EBIT growth 3YN/A
EBIT growth 5Y-7.67%
EBIT Next Year36.79%
EBIT Next 3Y17.14%
EBIT Next 5Y16.22%
FCF growth 1Y495.24%
FCF growth 3Y28.14%
FCF growth 5Y-3.38%
OCF growth 1Y179.8%
OCF growth 3Y15.37%
OCF growth 5Y-4.45%
ILLUMINA INC / ILMN FAQ
Can you provide the ChartMill fundamental rating for ILLUMINA INC?
ChartMill assigns a fundamental rating of 5 / 10 to ILMN.
Can you provide the valuation status for ILLUMINA INC?
ChartMill assigns a valuation rating of 6 / 10 to ILLUMINA INC (ILMN). This can be considered as Fairly Valued.
How profitable is ILLUMINA INC (ILMN) stock?
ILLUMINA INC (ILMN) has a profitability rating of 7 / 10.
What is the financial health of ILLUMINA INC (ILMN) stock?
The financial health rating of ILLUMINA INC (ILMN) is 5 / 10.
What is the expected EPS growth for ILLUMINA INC (ILMN) stock?
The Earnings per Share (EPS) of ILLUMINA INC (ILMN) is expected to grow by 96.03% in the next year.